|
1
|
Grünert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665.
2003.PubMed/NCBI
|
|
2
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh A, Greninger P, Rhodes D, Koopman L,
Violette S, Bardeesy N and Settleman J: A gene expression signature
associated with ‘K-Ras addiction’ reveals regulators of EMT and
tumor cell survival. Cancer Cell. 15:489–500. 2009.
|
|
6
|
Beer DG, Kardia SL, Huang CC, et al:
Gene-expression profiles predict survival of patients with lung
adenocarcinoma. Nat Med. 8:816–824. 2002.PubMed/NCBI
|
|
7
|
Potti A, Mukherjee S, Petersen R, Dressman
HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS,
West M, Harpole DH Jr and Nevins JR: A genomic strategy to refine
prognosis in early-stage non-small-cell lung cancer. New Eng J Med.
355:570–580. 2006. View Article : Google Scholar
|
|
8
|
Seike M, Yanaihara N, Bowman ED, Zanetti
KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J,
Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW and Harris CC: Use
of a cytokine gene expression signature in lung adenocarcinoma and
the surrounding tissue as a prognostic classifier. J Natl Cancer
Inst. 99:1257–1269. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seike M, Goto A, Okano T, Bowman ED,
Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, Gemma
A, Kudoh S, Croce CM and Harris CC: MiR-21 is an EGFR regulated
anti-apoptotic factor in lung cancer in never-smokers. Proc Natl
Acad Sci USA. 106:12085–12090. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saito RA, Watabe T, Horiguchi K, Kohyama
T, Saitoh M, Nagase T and Miyazono K: Thyroid transcription
factor-1 inhibits transforming growth factor-beta-mediated
epithelial-to-mesenchymal transition in lung adenocarcinoma cells.
Cancer Res. 69:2783–2791. 2009. View Article : Google Scholar
|
|
11
|
Thomson S, Buck E, Petti F, Griffin G,
Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial
to mesenchymal transition derived from repeated exposure to
gefitinib determines the sensitivity to EGFR inhibitors in A549, a
non-small cell lung cancer cell line. Cancer Res. 65:9455–9462.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yauch RL, Januario T, Eberhard DA, Cavet
G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S,
Modrusan Z, Lin CY, O’Neill V and Amler LC: Epithelial versus
mesenchymal phenotype determines in vitro sensitivity and predicts
clinical activity of erlotinib in lung cancer patients. Clin Cancer
Res. 11:8686–8698. 2005. View Article : Google Scholar
|
|
13
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition
derived from repeated exposure to gefitinib determines the
sensitivity to EGFR inhibitors in A549, a non-small cell lung
cancer cell line. Lung Cancer. 63:219–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soltermann A, Tischler V, Arbogast S,
Braun J, Probst-Hensch N, Weder W, Moch H and Kristiansen G:
Prognostic significance of epithelial-mesenchymal and
mesenchymal-epithelial transition protein expression in non-small
cell lung cancer. Clin Cancer Res. 14:7430–7437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bremnes RM, Veve R, Gabrielson E, Hirsch
FR, Baron A, Bemis L, Gemmill RM, Drabkin HA and Franklin WA:
Hirsch tissue microarray analysis used to evaluate biology and
prognostic significance of the E-cadherin pathway in non-small-cell
lung cancer. J Clin Oncol. 20:2417–2428. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deeb G, Wang J, Ramnath N, Slocum HK,
Wiseman S, Beck A and Tan D: Altered E-cadherin and epidermal
growth factor receptor expressions are associated with patient
survival in lung cancer: a study utilizing high-density tissue
microarray and immunohistochemistry. Mod Pathol. 17:430–439. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gemma A, Takenaka K, Hosoya Y, Matuda K,
Seike M, Kurimoto F, Ono Y, Uematsu K, Takeda Y, Hibino S,
Yoshimura A, Shibuya M and Kudoh S: Altered expression of several
genes in highly metastatic subpopulations of a human pulmonary
adenocarcinoma cell line. Eur J Cancer. 37:1554–1561. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gemma A, Li C, Sugiyama Y, Matsuda K,
Minegishi Y, Noro R, Nara M, Seike M, Yoshimura A, Ogawa N, Uesaka
H, Shionoya A, Kawakami A, Kosaihira S and Kudoh S: Anticancer drug
clustering in lung cancer based on gene expression profiles and
sensitivity database. BMC Cancer. 6:1742006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seike M, Kondo T, Mori Y, Gemma A, Kudoh
S, Sakamoto M, Yamada T and Hirohashi S: Proteomic analysis of
intestinal epithelial cells expressing stabilized beta catenin.
Cancer Res. 63:4641–4647. 2003.PubMed/NCBI
|
|
20
|
Okano T, Kondo T, Fujii K, Nishimura T,
Takano T, Ohe Y, Tsuta K, Matsuno Y, Gemma A, Kato H, Kudoh S and
Hirohashi S: Proteomic signature corresponding to the response to
gefitinib (Iressa, ZD1839), an epidermal growth factor receptor
tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res.
13:799–805. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bruey JM, Ducasse C, Bonniaud P, Ravagnan
L, Susin SA, Diaz-Latoud C, Gurbuxani S, Arrigo AP, Kroemer G,
Solary E and Garrido C: Hsp27 negatively regulates cell death by
interacting with cytochrome c. Nat Cell Biol. 2:645–652. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jia Y, Ransom RF, Shibanuma M, Liu C,
Welsh MJ and Smoyer WE: Identification and characterization of
hic-5/ARA55 as an hsp27 binding protein. J Biol Chem.
276:39911–39918. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhuang H, Jiang W, Cheng W, Qian K, Dong
W, Cao L, Huang Q, Li S, Dou F, Chiu JF, Fang XX, Lu M and Hua ZC:
Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to
TRAIL-induced apoptosis. Lung Cancer. 68:27–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu L, Chen S and Bergan RC: MAPKAPK2 and
HSP27 are downstream effectors of p38 MAP kinase-mediated matrix
metalloproteinase type 2 activation and cell invasion in human
prostate cancer. Oncogene. 25:2987–2998. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jäättelä M: Escaping cell death: survival
proteins in cancer. Exp Cell Res. 248:30–43. 2009.PubMed/NCBI
|
|
27
|
Yao H, Zhang Z, Xiao Z, Chen Y, Li C,
Zhang P, Li M, Liu Y, Guan Y, Yu Y and Chen Z: Identification of
metastasis associated proteins in human lung squamous carcinoma
using two-dimensional difference gel electrophoresis and laser
capture microdissection. Lung Cancer. 65:41–48. 2009. View Article : Google Scholar
|
|
28
|
Malusecka E, Krzyzowska-Gruca S,
Gawrychowski J, Fiszer-Kierzkowska A, Kolosza Z and Krawczyk Z:
Stress proteins HSP27 and HSP70i predict survival in non-small cell
lung carcinoma. Anticancer Res. 28:501–506. 2008.PubMed/NCBI
|
|
29
|
Berrieman HK, Cawkwell L, O’Kane SL, Smith
L and Lind MJ: Hsp27 may allow prediction of the response to
single-agent vinorelbine chemotherapy in non-small cell lung
cancer. Oncol Rep. 15:283–286. 2006.PubMed/NCBI
|
